SLCO2B1

Across TCGA pan-cancer cohorts, SLCO2B1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLCO2B1 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLCO2B1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLCO2B1 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and LSCC are the cancer types where SLCO2B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.312	0.516	.021	19	view →
CCRCC	DFS	Tertile	IV	0.108	0.758	.024	6	view →
LSCC	DFS	Tertile	II,III,IV	0.590	0.875	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLCO2B1–PDAC (DFS)

Open the PDAC breakdown →